First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $101M — +10.2% growth in a single year.
What’s Driving the Stock
1Zynex has secured a new partnership with a major healthcare provider, expected to increase device sales by 25% over the next year.
2The company is in the process of obtaining FDA approval for a next-generation electrotherapy device, which could significantly enhance its market position.
3Recent changes in insurance reimbursement policies are expected to favor Zynex's product offerings, potentially increasing demand.
4Zynex's gross margin has remained stable despite rising input costs, indicating strong pricing power.
5Increasing demand for non-invasive pain management solutions
6Growth in telehealth services enhancing device accessibility
7Changes in reimbursement policies for medical devices
8Market penetration in the physical therapy sector